No Data
Baiyunshan (00874.HK) saw a shareholding reduction of 0.348 million shares by Norges Bank.
According to the latest equity disclosure information from the Hong Kong Stock Exchange on November 27, 2024, baiyunshan ph (00874.HK) was sold by Norges Bank on the exchange at an average price of HKD 18.0525 per share, selling 0.348 million shares, involving approximately 6.2823 million Hong Kong dollars. After the shareholding, Norges Bank's latest number of shares held is 10.855 million shares, and the shareholding ratio has decreased from 5.09% to 4.94%.
Baiyunshan (00874.HK)'s subsidiary Guangzhou Medicine sells the first new underlying assets to Xingzheng Asset Management and receives a purchase price of 0.524 billion yuan.
Gelonghui reported on November 28 that baiyunshan ph (00874.HK) announced that on November 28, 2024, the company's non-wholly-owned subsidiary Guangzhou Medicine signed a "New Basic Asset Delivery Confirmation Letter" with Xingzheng Asset Management according to the Basic Asset Sale Agreement (Phase IV), confirming the sale of the first newly added basic asset to Xingzheng Asset Management and receiving a purchase price of 524,000,713.50 yuan.
Baiyunshan Pharma's Unit Gets Nod to Make Changes to Selaginella Jiangnanensis Tablets
Baiyunshan Pharma Gets Nod to Market Anti-Tumor Drug
Baiyunshan (600332.SH): Cefdinir granules have received a pharmaceutical registration certificate.
On November 25, Gelonghui reported that baiyunshan ph (600332.SH) announced that its holding subsidiary, Guangzhou baiyunshan ph Tianxin Pharmaceutical Co., Ltd. (referred to as 'Tianxin Pharmaceutical'), received the pharmaceutical registration certificate approved and issued by the National Medical Products Administration for Cefdinir Granules (50mg). Cefdinir Granules belong to the third generation of cephalosporin antibiotics, which mainly exert their bactericidal effect by inhibiting the synthesis of bacterial cell walls, making it a broad-spectrum antibiotic that was approved for market launch in 2002 in china. It is suitable for the treatment of Staphylococcus, Streptococcus, Pneumococcus, Streptococcus dysgalactiae, and Propionibacterium that are sensitive to Cefdinir.
Here's Why Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt Responsibly
Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down
